BR112017006925A2 - composições e kits para tratamento de prurido e métodos de uso das mesmas - Google Patents

composições e kits para tratamento de prurido e métodos de uso das mesmas

Info

Publication number
BR112017006925A2
BR112017006925A2 BR112017006925A BR112017006925A BR112017006925A2 BR 112017006925 A2 BR112017006925 A2 BR 112017006925A2 BR 112017006925 A BR112017006925 A BR 112017006925A BR 112017006925 A BR112017006925 A BR 112017006925A BR 112017006925 A2 BR112017006925 A2 BR 112017006925A2
Authority
BR
Brazil
Prior art keywords
kits
methods
treatment compositions
amylase
pruritus
Prior art date
Application number
BR112017006925A
Other languages
English (en)
Other versions
BR112017006925B1 (pt
Inventor
Beal Salamone Ann
Charles Salamone Joseph
Elizabeth Reilly Katelyn
Xiaoyu-Chen Leung Kelly
Original Assignee
Rochal Ind Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rochal Ind Llc filed Critical Rochal Ind Llc
Publication of BR112017006925A2 publication Critical patent/BR112017006925A2/pt
Publication of BR112017006925B1 publication Critical patent/BR112017006925B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01001—Alpha-amylase (3.2.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01002—Beta-amylase (3.2.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

é descrito um tratamento para prurido que se baseia na amilase. as amilases (a-, ß-, ¿-amilase) são conhecidas pela clivagem das ligações a-glicosídicas de polissacarídeos, produzindo fragmentos de carboidrato/açúcar de baixo peso molecular. verificou-se agora que a a-amilase é eficaz na redução do prurido (coceira) do tecido afetado.
BR112017006925-3A 2014-10-10 2015-10-08 Uso de uma composição prurítica enzimática na fabricação de um medicamento para o tratamento da sensação de coceira BR112017006925B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/511,988 2014-10-10
US14/511,988 US20160101166A1 (en) 2014-10-10 2014-10-10 Compositions and kits for treating pruritus and methods of using the same
PCT/US2015/054683 WO2016057789A1 (en) 2014-10-10 2015-10-08 Compositions and kits for treating pruritus and methods of using the same

Publications (2)

Publication Number Publication Date
BR112017006925A2 true BR112017006925A2 (pt) 2017-12-12
BR112017006925B1 BR112017006925B1 (pt) 2023-12-12

Family

ID=55653769

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006925-3A BR112017006925B1 (pt) 2014-10-10 2015-10-08 Uso de uma composição prurítica enzimática na fabricação de um medicamento para o tratamento da sensação de coceira

Country Status (12)

Country Link
US (2) US20160101166A1 (pt)
EP (1) EP3204038B1 (pt)
JP (1) JP6669334B2 (pt)
AU (1) AU2015330889B2 (pt)
BR (1) BR112017006925B1 (pt)
CA (1) CA2963812A1 (pt)
DK (1) DK3204038T3 (pt)
ES (1) ES2914615T3 (pt)
MX (1) MX2017004198A (pt)
NZ (1) NZ730769A (pt)
PT (1) PT3204038T (pt)
WO (1) WO2016057789A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238719B2 (en) 2014-10-10 2019-03-26 Rochal Industries, Llc Compositions and kits for enzymatic debridement and methods of using the same
US9592280B2 (en) * 2014-10-10 2017-03-14 Rochal Industries Llc Compositions and kits for enzymatic debridement and methods of using the same
JP6808628B2 (ja) * 2015-08-07 2021-01-06 株式会社カネカ 貼付剤
RU2647372C1 (ru) * 2017-04-17 2018-03-15 Александр Ливиевич Ураков Крем от обморожений
US20210361820A1 (en) * 2018-01-31 2021-11-25 Systagenix Wound Management, Limited Antimicrobial composition, dressing, dressing components, and method
US10961662B1 (en) 2019-12-23 2021-03-30 Polymer Ventures, Inc. Ash retention additive and methods of using the same
FR3108841B1 (fr) * 2020-04-06 2023-11-03 Algotherapeutix Composition pharmaceutique topique sous forme de gel aqueux comprenant au moins de l’amitriptyline
FR3127689A1 (fr) * 2021-10-01 2023-04-07 Algotherapeutix Composition pharmaceutique topique sous forme de gel comprenant au moins de l’amitriptyline pour son utilisation dans le traitement des douleurs neuropathiques du membre fantôme
FR3127688A1 (fr) * 2021-10-01 2023-04-07 Algotherapeutix Composition pharmaceutique topique sous forme de gel comprenant au moins de l’amitriptyline pour son utilisation dans le traitement des douleurs neuropathiques induites par un coronavirus

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2120667A (en) 1937-12-01 1938-06-14 Lakeland Foundation Therapeutic agent for use in the treatment of infection
US2917433A (en) 1956-04-02 1959-12-15 Rystan Company Stable aqueous papain topical compositions
US3003917A (en) * 1959-01-14 1961-10-10 Nat Drug Co Wound healing composition
US3409719A (en) 1967-05-23 1968-11-05 Baxter Laboratories Inc Debridement agent
WO1984002846A1 (en) 1983-01-21 1984-08-02 Advanced Drug Tech Enzyme ointment
US4719235A (en) 1984-10-16 1988-01-12 Gerald N. Kern Methods and compositions for treating viral infection
US4668228A (en) 1985-03-12 1987-05-26 Johnson & Johnson Products, Inc. Debriding tape
US4885310A (en) 1985-05-09 1989-12-05 Gerald N. Kern Anti-fungal methods and agent
US4717737A (en) 1985-06-05 1988-01-05 Gerald N. Kern Anti-bacterial methods and agent
US4772465A (en) 1986-10-27 1988-09-20 Miles Laboratories, Inc. Method of treating polymicrobial burn wound sepsis with a combination therapy of ciprofloxacin and pseudomonas immune globulin
US5206026A (en) 1988-05-24 1993-04-27 Sharik Clyde L Instantaneous delivery film
US5120656A (en) 1989-08-18 1992-06-09 Osteotech, Inc. Process for debriding bone
CA2041871C (en) * 1990-05-09 2000-07-11 Ruth A. Rosenthal Contact lens cleaning and disinfecting with combinations of polymeric quaternary ammonium compounds and enzymes
US5543149A (en) 1995-03-01 1996-08-06 Rubin; Stan M. Treatment for insect bites
US5670142A (en) 1996-07-08 1997-09-23 Donald Neudecker Treatment for itch of chicken pox
WO1999046368A2 (en) 1998-03-13 1999-09-16 Biomarin Pharmaceuticals Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment
US6548556B2 (en) 2000-12-27 2003-04-15 Healthpoint, Ltd. Stable enzymatic wound debrider
US7223386B2 (en) 2002-03-11 2007-05-29 Dow Corning Corporation Preparations for topical skin use and treatment
US20040076671A1 (en) 2002-10-21 2004-04-22 Aletha Tippett Methods and compositions for topical wound treatment
US20070237812A1 (en) * 2006-04-11 2007-10-11 Tyco Healthcare Group Multi-layer wound dressings
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
WO2005035010A1 (en) 2003-10-10 2005-04-21 Coloplast A/S Wound dressing containing proteolytic enzymes
IL165334A0 (en) 2004-11-22 2006-01-15 Mediwound Ltd Debriding composition from bromelain and methods of producing same
WO2008063229A2 (en) 2006-05-12 2008-05-29 Livingston James A Enzymatic debridement therapy for abnormal cell proliferation
US7629158B2 (en) 2006-06-16 2009-12-08 The Procter & Gamble Company Cleaning and/or treatment compositions
US8287858B2 (en) 2006-08-10 2012-10-16 Jon Barron Proteolytic enzyme formulations
EP2318521A1 (en) 2008-07-10 2011-05-11 Life Science Investments Ltd. Use of a mixture of superoxide dismutase and catalase for treating pruritus and alleviating its symptoms
RU2407512C1 (ru) * 2009-06-24 2010-12-27 Сергей Борисович Улитовский Безабразивная зубная паста, содержащая ферменты папаин, декстраназу, альфа-амилазу, калия или аммония тиоцианат, инвертазу или глюкоамилазу, глюкозооксидазу, лактопероксидазу, лизоцим или лактоферрин и лактулозу
JP5933542B2 (ja) 2010-07-29 2016-06-08 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 多糖類およびグリコシダーゼもしくはグリコシルトランスフェラーゼを用いるアクリレート誘導体のグリコシドを製造する方法
US8486664B2 (en) 2010-07-29 2013-07-16 Basf Se Enzymatic production of an ethylenically unsaturated glycoside using polysaccharides
US20120104047A1 (en) * 2010-11-01 2012-05-03 Lim Walter K Composition for Relief of Insect Bites and Stings and Apparatus and Method for Its Delivery
RU2013150536A (ru) 2011-05-12 2015-06-20 Смит & Невью Ортопедикс АГ Способ и топическая композиция для обработки ран, содержащая seaprose и его применение
EP2736486B1 (en) 2011-07-28 2019-03-06 3M Innovative Properties Company Wound-healing compositions and method of use
WO2013116732A1 (en) * 2012-02-02 2013-08-08 Curelon Llc Enzyme compositions and use thereof for wound healing
WO2013155476A1 (en) 2012-04-12 2013-10-17 Integrative Enzymatics, Inc. Composition and method for modulating inflammatory molecules with amylase
US20130287859A1 (en) 2012-04-26 2013-10-31 Lescarden Inc. Method for treating prupritus with cartilage extract
CN102973927A (zh) * 2012-11-29 2013-03-20 李安平 止痒卫生纸制造方法
US20150086529A1 (en) 2013-09-26 2015-03-26 Barbara Ann Hillenbrand Therapeutic Burn Gel

Also Published As

Publication number Publication date
AU2015330889A1 (en) 2017-04-27
US20160101166A1 (en) 2016-04-14
BR112017006925B1 (pt) 2023-12-12
DK3204038T3 (da) 2022-06-13
PT3204038T (pt) 2022-06-06
NZ730769A (en) 2024-02-23
ES2914615T3 (es) 2022-06-14
EP3204038B1 (en) 2022-05-04
JP2017530164A (ja) 2017-10-12
CA2963812A1 (en) 2016-04-14
JP6669334B2 (ja) 2020-03-18
EP3204038A4 (en) 2018-06-13
WO2016057789A1 (en) 2016-04-14
MX2017004198A (es) 2017-07-19
US20160199459A1 (en) 2016-07-14
EP3204038A1 (en) 2017-08-16
US10688159B2 (en) 2020-06-23
AU2015330889B2 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
BR112017006925A2 (pt) composições e kits para tratamento de prurido e métodos de uso das mesmas
BR112017022845A2 (pt) neoepítopos de câncer
BR112020002012A8 (pt) Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39
BR112018000601A2 (pt) moléculas de anticorpo que se ligam ao cd22
CO2019000099A2 (es) Composiciones que comprenden cepas bacterianas
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
CR20150476A (es) Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares
BR112017007379A2 (pt) moléculas de anticorpo para pd-l1 e usos das mesmas
MY192226A (en) Anti-tigit antigen-binding proteins and methods of use thereof
CR20150592A (es) Composiciones y métodos para alterar la señalización del segundo mensajero
MX2016002571A (es) Regulador de ph de transduccion.
MX2017001815A (es) Celulas hospederas modificadas y oligosacaridos hibridos para su uso en produccion de bioconjugados.
MX370573B (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
BR112015009162A2 (pt) Gel de ácido hialurônico reticulado, processo para preparar um gel de ácido hialurônico reticulado, composições dermatológicas, kit e uso de um gel de ácido hialurônico reticulado
WO2016014434A3 (en) Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
CL2013003455A1 (es) Uso de compuestos inhibidores de sglt-2 derivados de benceno, sustituidos por glucopiranosilo para prevenir, desacelerar la progresion, retrasar o tratar un trastorno metabolico en un pacientes con un agente neuroleptico; uso de la combinacion del inhibidor de sglt2 con un neuroleptico; y composicion farmaceutica de la combinacion.
BR112013028832A2 (pt) composição alimentícia, uso de éter de celulose e método para melhorar uma ou mais das propriedades de uma composição alimentícia
CO6950477A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
BR112017005997A2 (pt) método
BR112017006939A2 (pt) composições e kits para o desbridamento de enzima e métodos de utilização dos mesmos
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/10/2015, OBSERVADAS AS CONDICOES LEGAIS